Table 3.
Univariate and multivariate Cox proportional hazards regression analyses for progression free survival of uterine sarcoma patients (n =112)
| Parameter | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | |
| Histological types | <0.001 | <0.001 | ||
| AS(N=10) | 1 (referent) | 1 (referent) | ||
| ULMS(N=41) | 14.062(1.623-121.837) | 0.016 | 12.848(1.711-96.487) | 0.013 |
| LG-ESS(N=43) | 2.727(0.307-24,217) | 0.368 | 3.476(0.438-27.594) | 0.239 |
| HG-ESS(N=13) | 108.000(5.922-1969.539) | 0.002 | 24.223(3.039-193.068) | 0.003 |
| UUS(N=5) | 36.000(1.772-731.562) | 0.020 | 40.268(4.307-376.520) | 0.001 |
| FIGO stage | ||||
| Stage I | 1 (referent) | 1 (referent) | ||
| Stage II-IV | 3.300(1.077-10.114) | 0.037 | 3.031(1.524-6.029) | 0.002 |
| Lymphadenectomy | ||||
| Yes | 1 (referent) | |||
| No | 0.939(0.444-1.986) | 0.869 | ||
| Initial surgery | ||||
| Laparotomy | 1 (referent) | |||
| Laparoscopy | 1.604(0.746-3.451) | 0.227 | ||
| Ovariectomy | ||||
| Yes | 1 (referent) | |||
| No | 1.375(0.531-3.562) | 0.512 | ||
| Age(years) | ||||
| ≤50 | 1 (referent) | |||
| >50 | 1.852 (10.862-7.255) | 0.114 | ||
| Size | ||||
| ≤7.5 | 1 (referent) | 1 (referent) | ||
| >7.5 | 1.998(0.926-4.312) | 0.078 | 2.100(1.136-3.881) | 0.018 |
| Menstrual status | ||||
| Premenopausal | 1 (referent) | |||
| Postmenopausal | 2.743 (1.199-6.272) | 0.017 | ||
| NLR | ||||
| ≤2.14 | 1 (referent) | 1 (referent) | ||
| >2.14 | 2.7271(1.199-6.201) | 0.017 | 1.884(0.938-3.625) | 0.076 |
| PLR | ||||
| ≤128.5 | 1 (referent) | |||
| >128.5 | 3.419 (1.369-8.541) | 0.009 | ||
Abbreviation: AS Adenosarcoma, ULMS Uterine leiomyosarcoma, LG-ESS Low-grade endometrial stromal sarcoma; HG-ESS High-grade endometrial stromal sarcoma, UUS Undifferentiated uterine sarcoma, NLR Neutrophil to lymphocyte ratio, PLR Platelet to lymphocyte ratio, HR Hazard ratio, CI Confidence interval